Drugs / magnesium-cannabidiolic acid
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2/3 | NCT04103814 Comparator | Oct 2019 → May 2023 | osteoarthritis, toe, toe, misshapen | Rush University Medical Center | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | magnesium-cannabidiolic acid | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04103814 ↗ |
| Known as | Mg-CBDa | “Patients will receive Mg-CBDa (magnesium-cannabidiolic acid) cream for topical treatment of hallux rigidus or hallux valgus.” NCT04103814 ↗ |
| Route | Topical | “for topical treatment of hallux rigidus or hallux valgus” NCT04103814 ↗ |